Size: | Price | Quantity | |
---|---|---|---|
20 mg | $50.00 | ||
100 mg | $150.00 |
Pomalidomide (19171-19-8) is a thalidomide analog that inhibits cereblon (CRBN), an E3 ubiquitin ligase, IC50 ~3 μM for CRBN-DDB1 complex.1 Displays antiangiogenic and immunomodulatory activity in vivo potently inhibiting the production of TNFα and IL-2.2 Promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.3 Conjugation with other ligands is a strategy to target proteins for in vivo proteasomal degradation via PROTACS.4,5
References/Citations:
1) Lopez-Girona et al. (2012), Cereblon is direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide; Leukemia, 26 2326
2) Zhu et al. (2013), Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma; Leukemia Lymphoma, 54 683
3) Donovan et al. (2018), Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome; Elife, 7 e38430
4) Winter et al. (2015), DRUG DEVELOPMENT. Phthalimide conjunction as a strategy for in vivo target protein degradation; Science, 348 1376
5) Lohbeck and Miller (2016), Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development; Bioorg. Med. Chem. Lett., 26 5260
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Pomalidomide (19171-19-8) is a thalidomide analog that inhibits cereblon (CRBN), an E3 ubiquitin ligase, IC50 ~3 μM for CRBN-DDB1 complex.1 Displays antiangiogenic and immunomodulatory activity in vivo potently inhibiting the production of TNFα and IL-2.2 Promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.3 Conjugation with other ligands is a strategy to target proteins for in vivo proteasomal degradation via PROTACS.4,5
References/Citations:
1) Lopez-Girona et al. (2012), Cereblon is direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide; Leukemia, 26 2326
2) Zhu et al. (2013), Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma; Leukemia Lymphoma, 54 683
3) Donovan et al. (2018), Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome; Elife, 7 e38430
4) Winter et al. (2015), DRUG DEVELOPMENT. Phthalimide conjunction as a strategy for in vivo target protein degradation; Science, 348 1376
5) Lohbeck and Miller (2016), Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development; Bioorg. Med. Chem. Lett., 26 5260
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.